SEHK:6855
SEHK:6855Biotechs

Assessing Ascentage Pharma (SEHK:6855) Valuation Following Major Data Publication on Olverembatinib in Rare GIST Subtype

Ascentage Pharma Group International (SEHK:6855) garnered investor interest after publishing new data from a Phase Ib study for its drug olverembatinib in patients with SDH-deficient gastrointestinal stromal tumors. See our latest analysis for Ascentage Pharma Group International. Following the announcement of encouraging new results for olverembatinib, Ascentage Pharma Group International has continued to capture investor attention, even as its share price has pulled back 6.4% over the past...
SEHK:1757
SEHK:1757Construction

Affluent Foundation (SEHK:1757): Net Profit Margin Falls to 0.3%, Challenging Bullish Narratives

Affluent Foundation Holdings (SEHK:1757) just released its H1 2026 results, posting total revenue of $115.3 million HKD and basic EPS of 0.000799 HKD. Looking back, the company saw revenue trend from $70.4 million HKD in H2 2024 to $125.4 million HKD in H1 2025, before landing at $115.3 million HKD in this latest update. EPS moved from 0.001429 HKD to 7.8e-05 HKD during the same periods. Margins were tight across these results, with profitability metrics flashing a caution light for investors...
SEHK:1499
SEHK:1499Construction

OKG Technology (SEHK:1499) Margin Stagnation Reinforces Investor Concerns Despite H1 2026 Revenue Growth

OKG Technology Holdings (SEHK:1499) has just reported its H1 2026 results, with total revenue at 340.9 million HKD and a basic EPS of -0.001994 HKD. The numbers reflect a continuation of unprofitable results for the company. Revenue has grown from 195.7 million HKD in H1 2025 and 123.5 million HKD in H1 2024. Investors will be closely watching margins as profit trends remain negative. See our full analysis for OKG Technology Holdings. Next up, we’ll see how these results measure up against...
SEHK:9969
SEHK:9969Biotechs

InnoCare Pharma (SEHK:9969) Valuation in Focus After Revenue Growth and Narrowed Losses

InnoCare Pharma (SEHK:9969) just released its latest earnings, reporting both higher revenue and a significantly smaller net loss for the nine months through September. These results are giving investors plenty to analyze right now. See our latest analysis for InnoCare Pharma. Fresh from reporting sharply reduced net losses and steadily rising revenue, InnoCare Pharma has enjoyed some serious momentum. Its share price has soared 160.98% year-to-date, and over the past year, investors have...
SEHK:1050
SEHK:1050Electronic

Asian Market Insights: 3 Penny Stocks With Market Caps Over US$20M

Amidst global concerns about AI valuations and economic uncertainties, Asian markets have mirrored some of the cautious sentiment seen in other regions. For investors interested in exploring smaller or newer companies, penny stocks continue to present intriguing opportunities despite their somewhat dated terminology. These stocks, often representing under-the-radar growth potential at lower price points, can offer significant upside when backed by strong financial health and solid fundamentals.
SEHK:981
SEHK:981Semiconductor

A Fresh Look at SMIC (SEHK:981) Valuation Following Higher Sales and Upbeat Q4 Guidance

Semiconductor Manufacturing International (SEHK:981) just released its latest earnings, showing increased sales and net income for the nine months ending September 30, 2025. The company also projected stable or slightly higher revenue for the upcoming quarter. See our latest analysis for Semiconductor Manufacturing International. On the heels of stronger sales and upbeat guidance, Semiconductor Manufacturing International’s 1-year total shareholder return stands out at 167.9%, showing...
SEHK:270
SEHK:270Water Utilities

Guangdong Investment (SEHK:270): Reviewing Valuation After Securing HKD 2.25 Billion Debt Facility

Guangdong Investment (SEHK:270) revealed acceptance of a HKD 2.25 billion committed term loan facility on 19 November 2025. The loan is aimed at funding general corporate needs and refinancing existing debt, subject to specific ownership-related covenants. See our latest analysis for Guangdong Investment. The new loan announcement comes as Guangdong Investment’s share price has steadily gained traction this year, climbing 14.8% year-to-date, with the latest move up to HK$7.59. Momentum has...